Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization in the United States ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Myasthenia gravis is a rare, chronic autoimmune disorder that causes serious muscle weakness.

ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis ...

Rare disease community members take action in June to spread awareness and advocate for better treatments and a cure for myasthenia gravis Global MG Community turns Awareness into Action to ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the ...

The Phase 3 AURORA trial tests Descartes-08 against a placebo in patients with acetylcholine receptor autoantibody positive myasthenia gravis. How many participants are enrolled in the AURORA trial?

As the world's first innovative biologic drug targeting both BLyS and APRIL for the treatment of myasthenia gravis (MG), Telitacicept's approval not only brings new treatment options to patients ...